Skip to main content
Equibles
AXIM logo

AXIM · Axim Biotechnologies, Inc.

Track AXIM — free

Use AXIM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AXIM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+3.33%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2024

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.”
View the 10-Q filed Aug 19, 2024
Market Cap
$905,876
Shares
301.96M
Volume · Oct 23 114K Avg daily vol (3M) 387.06K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.02 Avg vol 30d201K Short int83K · 0.0% float · 1.0d Short vol89% DataJan 2020–Oct 2026 Filing10-Q · Aug 19

Up next

Latest filing: 10-Q
filed Aug 19, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$92,650
Trailing 12 months
Net income (TTM)
−$4.14M
Trailing 12 months
Revenue growth YoY
+76.0%
Year over year
Operating margin
-2,497.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$180,448
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+78.2%
Year over year · more shares
Price change (1Y)
-61.3%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19.5 · elevated Equity put/call 0.67
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −51%
below
Price vs 50-day avg −14%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 2%
near low
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −48%
trailing
YTD return −72%
this year
Relative strength −54%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.03% of float · ▼ -8.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Squeeze score 28
low risk · 0–100
Fundamentals
Fair
Revenue growth +345%
Y/Y
Gross margin 0%
EPS growth 0%
Y/Y
Free cash flow $-1.0M
Balance sheet $75.4K
net debt
Quant / Vol
risk profile
Very High
Volatility 207%
annualized · 1-yr
Max drawdown −89%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−51% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.03% of float · ▼ -8.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0 Now $0 · 2% Range high $0
vs 200-day avg -51% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AXIM
Axim Biotechnologies, Inc.
this stock
$905,876 -71.8% +345.3% — 0.0%
VRTX
Vertex Pharmaceuticals Inc
 $132.80B +15.6% +46.2% 30.5 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.88B +4.3% +20.8% 19.9 2.1%
MRNA
Moderna, Inc.
 $79.89B +578.5% +4.3% — 7.7%
CSLLY
Csl Ltd
 $66.42B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
MassMutual Private Wealth…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
82.6K
Days to cover
1.0d
Change
-7.8K sh
View
Short Volume
Short vol %
89%
As of
Oct 23, 2026
Short Total
View
Fails to Deliver
FTD shares
5.6K
Value
$0
As of
Apr 6, 2026
View
Off-Exchange
Off-exchange %
70.6%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$39.5K
Net income (FY)
$-8.1M
EPS diluted
$-0.04
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 15, 2024
This year
0
View
Proposed Sales
Value
$76.1K
Shares
845.0K
Filed
Oct 7, 2022
View
Exempt Offerings
Offering
$5.0M
Filed
Jun 15, 2020
View

Performance

5D 20D 120D MTD YTD
AXIM -8.8% -16.2% -48.3% -8.8% -71.8%
SPY -0.4% -1.5% +5.8% -0.4% +11.5%
vs SPY -8.4% -14.7% -54.2% -8.5% -83.3%
Key facts CIK 1514946 CUSIP 05463V100 Visit website Investor relations